Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8989147 | 0.92 | ADRB2 (0.38) | TSHRLMNAADRB2ADRB1ADRB3 | |
| SCHEMBL20145107 | 0.88 | THRB (0.44) | TSHRLMNACA1CA2THRB | |
| SCHEMBL11374678 | 0.88 | THRB (0.44) | TSHRLMNACA1CA2THRB | |
| SCHEMBL3879551 | 0.88 | ADRB2 (0.39) | TSHRLMNAADRB2ADRB1ADRB3 | |
| SCHEMBL1189494 | 0.87 | ADRB2 (0.35) | TSHRLMNAADRB2ADRB1ADRB3 | |
| SCHEMBL18771217 | 0.87 | DNM1 (0.42) | TSHRLMNAADRB2ADRB1ADRB3 | |
| SCHEMBL11657019 | 0.84 | ADRB2 (0.36) | TSHRLMNAADRB2ADRB1ADRB3 | |
| SCHEMBL15256842 | 0.83 | DNM1 (0.44) | TSHRADRB2ADRB1ADRB3CYP3A4 | |
| SCHEMBL11622968 | 0.82 | THRB (0.38) | TSHRCA1CA2THRB | |
| SCHEMBL29670528 | 0.82 | CYP3A4 (0.32) | ADRB2ADRB1ADRB3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119613414-A | Non-azolanet Process for the preparation of tam | 上海皓元医药股份有限公司 | 2025-03-14 | — | — | CN | claimed |
| EP-4452838-A1 | PROCESS FOR REMOVING WATER FROM BIS(FLUOROSULFONYL)IMIDE SOLUTIONS | SPECIALTY OPERATIONS FRANCE (FR) | 2024-10-30 | — | — | EP | claimed |
| US-12059467-B2 | Low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, preparation method thereof, and topical sustained release drug delivery formulation including same | ANHUI UNIVERSITY (CN) | 2024-08-13 | — | — | US | claimed |
| CN-118434672-A | Method for removing water from bis (fluorosulfonyl) imide solution | 法国特种经营公司 | 2024-08-02 | — | — | CN | claimed |
| US-20240108728-A1 | IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME | ANHUI UNIVERSITY (CN) | 2024-04-04 | — | — | US | claimed |
| WO-2023221320-A1 | IMPROVED LOW-TOXICITY AND HIGHLY EFFICIENT PHARMACEUTICAL EXCIPIENT OF ORTHOESTER MIXTURE, METHOD FOR PREPARING SAME, AND LOCAL SUSTAINED-RELEASE PREPARATION COMPRISING SAME | 安徽大学 | 2023-11-23 | — | — | WO | claimed |
| EP-4242173-A1 | PURIFICATION OF HYDROGEN BIS(FLUOROSULFONYL)IMIDE | SPECIALTY OPERATIONS FRANCE (FR) | 2023-09-13 | — | — | EP | claimed |
| WO-2023118115-A1 | PROCESS FOR REMOVING WATER FROM BIS(FLUOROSULFONYL)IMIDE SOLUTIONS | RHODIA OPERATIONS (FR) | 2023-06-29 | — | — | WO | claimed |
| US-4252738-A | 1,2-Halohydrincarboxylic acid esters and a process for their preparation | BAYER AKTIENGESELLSCHAFT (DE) | 1981-02-24 | — | — | US | claimed |
| US-4025539-A | Process for preparing 2-substituted or unsubstituted geranyl acetic acids and esters thereof | KURARAY CO., LTD. (JA) | 1977-05-24 | — | — | US | claimed |
| CN-121154837-B | Crosslinked nano prodrug, nano self-assembled hydrogel precursor tablet prepared from crosslinked nano prodrug and application of nano self-assembled hydrogel precursor tablet | ANHUI UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-4626984-A1 | PROCESS | Jotun A/S (NO) | 2025-10-08 | — | — | EP | disclosed |
| EP-4600314-A2 | FOULING RELEASE COATING COMPOSITION | Jotun A/S (NO) | 2025-08-13 | — | — | EP | disclosed |
| EP-4222223-B1 | FOULING RELEASE COATING COMPOSITION | JOTUN AS (NO) | 2025-07-02 | — | — | EP | disclosed |
| CN-119955408-A | Antifouling coating composition and application thereof | 中国科学院宁波材料技术与工程研究所 | 2025-05-09 | — | — | CN | disclosed |
| US-4692426-A | Phosphite-promoted ruthenium-cobalt catalysts for the dealkoxyhydroxymethylation of acetals to form glycol ethers | SUN REFINING AND MARKETING COMPANY (US) | 1987-09-08 | — | — | US | disclosed |
| US-4252738-A | 1,2-Halohydrincarboxylic acid esters and a process for their preparation | BAYER AKTIENGESELLSCHAFT (DE) | 1981-02-24 | — | — | US | disclosed |
| US-4113968-A | FROM A 1-HALO-3-ALKENE-2-OL | KURARAY CO., LTD. (JP) | 1978-09-12 | — | — | US | disclosed |
| US-4025539-A | Process for preparing 2-substituted or unsubstituted geranyl acetic acids and esters thereof | KURARAY CO., LTD. (JA) | 1977-05-24 | — | — | US | disclosed |
| US-3975381-A | Process for preparing γ-lactone derivatives | SAGAMI CHEMICAL RESEARCH CENTER (JA) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108728-A1 | IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME | TLR7, PON1, MYD88 | TSHR 3221/4885LMNA 4613/4885ADRB2 933/4885 |
| US-12059467-B2 | Low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, preparation method thereof, and topical sustained release drug delivery formulation including same | TLR7, PON1, MYD88 | TSHR 3173/4885LMNA 4595/4885ADRB2 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.